SHILPAMED
Shilpa Medicare Limited
Each stock's 10,000-path forecast, rendered as light.
Shilpa Medicare Limited (SHILPAMED) Stock Analysis & Case Study
Is SHILPAMED a good buy? The data-driven verdict.
Shilpa Medicare Limited (SHILPAMED) trades at ₹739,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Shilpa Medicare Limited (SHILPAMED) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 50.8× earnings, ROE of 9.4%, a 52% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SHILPAMED fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SHILPAMED ranks against the 2,373 companies in our screener
- SHILPAMED's market cap of 14,859 Cr ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SHILPAMED's book value of ₹132 ranks in the 61st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SHILPAMED's promoter holding of 40.1% ranks in the 16th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SHILPAMED's 3-year profit (PAT) growth of 109.0% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SHILPAMED's 3-year revenue growth of 14.0% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SHILPAMED's debt-to-equity ratio of 0.25x is lower than 57% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is SHILPAMED overvalued? SHILPAMED P/E vs peers
SHILPAMED trades at 50.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
SHILPAMED share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of SHILPAMED history (10%/yr drift, 43%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SHILPAMED 2027 | ₹441 | ₹772 | ₹1,352 | +2% |
| SHILPAMED 2028 | ₹360 | ₹785 | ₹1,715 | +3% |
| SHILPAMED 2029 | ₹305 | ₹798 | ₹2,088 | +5% |
| SHILPAMED 2030 | ₹267 | ₹812 | ₹2,471 | +7% |
| SHILPAMED 2031 | ₹233 | ₹825 | ₹2,918 | +9% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SHILPAMED goes up, or doubles?
The bull case for SHILPAMED
- Shilpa Medicare Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,088.
The bear case & risks
- SHILPAMED's P/E of 52.3x is lower than 25% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SHILPAMED's return on equity of 9.4% ranks in the 45th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹305.
SHILPAMED volatility & expected range, how bumpy is the ride?
Over the last 9.8 years SHILPAMED compounded at 10%/year with annualized volatility of 43%. That volatility implies a 1-year 80% range of ₹441-₹1,352, the honest backbone behind any single price target.
SHILPAMED price forecast, the full 60-month probability fan
SHILPAMED price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SHILPAMED hits common targets within the simulated horizon?
Full multi-horizon detail on the SHILPAMED price target & forecast page.
SHILPAMED Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SHILPAMED scores 6/8, mixed financial health.
SHILPAMED MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy SHILPAMED with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.54% | 2.8× |
| Zerodha | 35.54% | 2.8× |
| Groww | 35.55% | 2.8× |
| Dhan | 35.54% | 2.8× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 35.55% | 2.8× |
| Pocketful | 35.00% | 2.9× |
| FyersCHEAPEST | 34.48% | 2.9× |
| Anand Rathi | 35.54% | 2.8× |
| Bajaj Broking | 40.00% | 2.5× |
| Share India | 34.74% | 2.9× |
Compare every broker on the SHILPAMED MTF page.
About Shilpa Medicare Limited: sector, index & market-cap context
Shilpa Medicare Limited (SHILPAMED) is a small-cap NSE-listed company, with a market capitalisation of ₹14,458 Cr. See more stocks on our screener.
How the SHILPAMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Shilpa Medicare Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SHILPAMED analysis, FAQs
Is Shilpa Medicare Limited (SHILPAMED) a good buy?
On the numbers, Shilpa Medicare Limited (SHILPAMED) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 50.8× earnings, ROE of 9.4%, a 52% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SHILPAMED overvalued or undervalued?
SHILPAMED trades at 50.8× earnings, expensive versus the ~22× long-run Nifty average.
What is the SHILPAMED share price target for 2031?
SHILPAMED's probability-weighted 2031 median target is ₹825, with an 80% range of ₹233-₹2,918 (10,000-path Monte-Carlo).
What is the probability SHILPAMED doubles in 5 years?
The modelled probability of SHILPAMED reaching ₹1,520 (2×) within 5 years is 26%.
What is the bull case for SHILPAMED?
Shilpa Medicare Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in SHILPAMED?
SHILPAMED's P/E of 52.3x is lower than 25% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SHILPAMED's return on equity of 9.4% ranks in the 45th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.